ICD-10-CM Code C57.00

Malignant neoplasm of unspecified fallopian tube

Version 2020 Billable Code Diagnoses For Females Only

Valid for Submission

C57.00 is a billable code used to specify a medical diagnosis of malignant neoplasm of unspecified fallopian tube. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C57.00 might also be used to specify conditions or terms like any t/any n and m1 , carcinoma of fallopian tube, malignant tumor involving an organ by direct extension from fallopian tube, malignant tumor involving an organ by separate metastasis from fallopian tube, malignant tumor involving bladder by direct extension from fallopian tube, malignant tumor involving bladder by separate metastasis from fallopian tube, etc

The code C57.00 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.

ICD-10:C57.00
Short Description:Malignant neoplasm of unspecified fallopian tube
Long Description:Malignant neoplasm of unspecified fallopian tube

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:

  • Diagnoses for females only - Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, this code applies to FEMALES only .

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Any T/Any N and M1
  • Carcinoma of fallopian tube
  • Malignant tumor involving an organ by direct extension from fallopian tube
  • Malignant tumor involving an organ by separate metastasis from fallopian tube
  • Malignant tumor involving bladder by direct extension from fallopian tube
  • Malignant tumor involving bladder by separate metastasis from fallopian tube
  • Malignant tumor involving left ovary by direct extension from fallopian tube
  • Malignant tumor involving left ovary by separate metastasis from fallopian tube
  • Malignant tumor involving rectum by direct extension from fallopian tube
  • Malignant tumor involving rectum by separate metastasis from fallopian tube
  • Malignant tumor involving right ovary by separate metastasis from fallopian tube
  • Malignant tumor involving uterine cervix by direct extension from fallopian tube
  • Malignant tumor involving uterine cervix by separate metastasis from fallopian tube
  • Malignant tumor involving uterine corpus by direct extension from fallopian tube
  • Malignant tumor involving uterine corpus by separate metastasis from fallopian tube
  • Malignant tumor involving vagina by direct extension from fallopian tube
  • Malignant tumor involving vagina by separate metastasis from fallopian tube
  • Malignant tumor involving vulva by direct extension from fallopian tube
  • Malignant tumor involving vulva by separate metastasis from fallopian tube
  • Malignant tumor of fallopian tube
  • pM1
  • pN1
  • Primary adenocarcinoma of fallopian tube
  • Primary malignant neoplasm of fallopian tube
  • pT1
  • pT1a
  • pT1c
  • pT1c category
  • pT2
  • pT2a
  • pT2b
  • pT2c
  • pT2c category
  • pT3
  • pT3 and/or N1
  • pT3a
  • pT3b
  • pT3c
  • pT3c and/or N1
  • pT3c category
  • Secondary malignant neoplasm of body of uterus
  • Secondary malignant neoplasm of cervix uteri
  • Secondary malignant neoplasm of left ovary
  • Secondary malignant neoplasm of rectum
  • Secondary malignant neoplasm of right ovary
  • Secondary malignant neoplasm of vagina
  • Secondary malignant neoplasm of vulva
  • T1
  • T1a : Tumor limited to one fallopian tube without penetrating the serosal surface, no ascites
  • T1c with extension into or through the tubal serosa; or with malignant cells in ascites or peritoneal washings: FALLOPIAN TUBE: Salpingectomy
  • T2 with pelvic extension
  • T2a : Fallopian tube tumor with extension and/or metastasis to the uterus and/or ovaries
  • T2b : Fallopian tube/ovarian tumor with extension to other pelvic structures
  • T2c with malignant cells in ascites or peritoneal washings
  • T3 and/or N1 with peritoneal implants outside the pelvis and/or regional lymph node metastasis
  • T3a : Fallopian tube/ovarian tumor with microscopic peritoneal metastasis beyond pelvis
  • T3b : Fallopian tube/ovarian tumor with macroscopic peritoneal metastasis beyond pelvis < 2 cm in greatest dimension
  • T3c : Fallopian tube/ovarian tumor with peritoneal metastasis beyond pelvis > 2 cm in greatest dimension and/or regional lymph node metastasis

Diagnostic Related Groups

The ICD-10 code C57.00 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2020.

  • 736 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC
  • 737 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC
  • 738 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC
  • 739 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC
  • 740 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC
  • 741 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC

Convert C57.00 to ICD-9

  • 183.2 - Mal neo fallopian tube (Approximate Flag)

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of female genital organs (C51-C58)
      • Malignant neoplasm of other and unsp female genital organs (C57)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Information for Patients


Uterine Cancer

The uterus, or womb, is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type is also called endometrial cancer.

The symptoms of uterine cancer include

  • Abnormal vaginal bleeding or discharge
  • Trouble urinating
  • Pelvic pain
  • Pain during intercourse

Uterine cancer usually happens after menopause. It is more common in women who have obesity. You also have a higher risk if you took estrogen-only hormone replacement therapy (menopausal hormone therapy) for many years.

Tests to find uterine cancer include a pelvic exam, imaging tests, and a biopsy. The most common treatment is a hysterectomy, which is surgery to remove the uterus. Sometimes the surgery also removes the ovaries and fallopian tubes. Other treatments include hormone therapy, radiation therapy, and chemotherapy. Some women get more than one type of treatment.

NIH: National Cancer Institute


[Learn More]